KRAS Inhibitors Market Report: Trends, Forecast and Competitive Analysis to 2030
Lucintel has been in the business of market research and management consulting since 2000 and has published over 1000 market intelligence reports in various markets / applications and served over 1,000 clients worldwide. This study is a culmination of four months of full-time effort performed by Lucintel's analyst team. The analysts used the following sources for the creation and completion of this valuable report:
In-depth interviews of the major players in this market
Detailed secondary research from competitors’ financial statements and published data
Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
A compilation of the experiences, judgments, and insights of Lucintel’s professionals, who have analyzed and tracked this market over the years.
Extensive research and interviews are conducted across the supply chain of this market to estimate market share, market size, trends, drivers, challenges, and forecasts. Below is a brief summary of the primary interviews that were conducted by job function for this report.
Thus, Lucintel compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. Lucintel then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process. The figure below is a graphical representation of Lucintel’s research process.
In-depth interviews of the major players in this market
Detailed secondary research from competitors’ financial statements and published data
Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
A compilation of the experiences, judgments, and insights of Lucintel’s professionals, who have analyzed and tracked this market over the years.
Extensive research and interviews are conducted across the supply chain of this market to estimate market share, market size, trends, drivers, challenges, and forecasts. Below is a brief summary of the primary interviews that were conducted by job function for this report.
Thus, Lucintel compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. Lucintel then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process. The figure below is a graphical representation of Lucintel’s research process.
1. EXECUTIVE SUMMARY
2. GLOBAL KRAS INHIBITORS MARKET : MARKET DYNAMICS
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2018 TO 2030
3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global KRAS Inhibitors Market Trends (2018-2023) and Forecast (2024-2030)
3.3: Global KRAS Inhibitors Market by Cancer Type
3.3.1: Lung Cancer
3.3.2: Pancreatic Cancer
3.3.3: Colorectal Cancer
3.3.4: Others
3.4: Global KRAS Inhibitors Market by End Use
3.4.1: Clinic Laboratories
3.4.2: Cancer Diagnostic Centers
3.4.3: Hospitals
3.4.4: Cancer Research Institutes
3.4.5: Academic Institutions
3.4.6: Others
4. MARKET TRENDS AND FORECAST ANALYSIS BY REGION FROM 2018 TO 2030
4.1: Global KRAS Inhibitors Market by Region
4.2: North American KRAS Inhibitors Market
4.2.2: North American KRAS Inhibitors Market by End Use: Clinic Laboratories, Cancer Diagnostic Centers, Hospitals, Cancer Research Institutes, Academic Institutions, and Others
4.3: European KRAS Inhibitors Market
4.3.1: European KRAS Inhibitors Market by Cancer Type: Lung Cancer, Pancreatic Cancer, Colorectal Cancer, and Others
4.3.2: European KRAS Inhibitors Market by End Use: Clinic Laboratories, Cancer Diagnostic Centers, Hospitals, Cancer Research Institutes, Academic Institutions, and Others
4.4: APAC KRAS Inhibitors Market
4.4.1: APAC KRAS Inhibitors Market by Cancer Type: Lung Cancer, Pancreatic Cancer, Colorectal Cancer, and Others
4.4.2: APAC KRAS Inhibitors Market by End Use: Clinic Laboratories, Cancer Diagnostic Centers, Hospitals, Cancer Research Institutes, Academic Institutions, and Others
4.5: ROW KRAS Inhibitors Market
4.5.1: ROW KRAS Inhibitors Market by Cancer Type: Lung Cancer, Pancreatic Cancer, Colorectal Cancer, and Others
4.5.2: ROW KRAS Inhibitors Market by End Use: Clinic Laboratories, Cancer Diagnostic Centers, Hospitals, Cancer Research Institutes, Academic Institutions, and Others
5. COMPETITOR ANALYSIS
5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter’s Five Forces Analysis
6. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS
6.1: Growth Opportunity Analysis
6.1.1: Growth Opportunities for the Global KRAS Inhibitors Market by Cancer Type
6.1.2: Growth Opportunities for the Global KRAS Inhibitors Market by End Use
6.1.3: Growth Opportunities for the Global KRAS Inhibitors Market by Region
6.2: Emerging Trends in the Global KRAS Inhibitors Market
6.3: Strategic Analysis
6.3.1: New Product Development
6.3.2: Capacity Expansion of the Global KRAS Inhibitors Market
6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global KRAS Inhibitors Market
6.3.4: Certification and Licensing
7. COMPANY PROFILES OF LEADING PLAYERS
7.1: Amgen
7.2: Boehringer Ingelheim
7.3: BridgeBio Pharma
7.4: Erasca
7.5: Innovent Biologics
7.6: Incyte
7.7: Mirati Therapeutics
7.8: Novartis
7.9: Jemincare
7.10: Cardiff Oncology
2. GLOBAL KRAS INHIBITORS MARKET : MARKET DYNAMICS
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2018 TO 2030
3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global KRAS Inhibitors Market Trends (2018-2023) and Forecast (2024-2030)
3.3: Global KRAS Inhibitors Market by Cancer Type
3.3.1: Lung Cancer
3.3.2: Pancreatic Cancer
3.3.3: Colorectal Cancer
3.3.4: Others
3.4: Global KRAS Inhibitors Market by End Use
3.4.1: Clinic Laboratories
3.4.2: Cancer Diagnostic Centers
3.4.3: Hospitals
3.4.4: Cancer Research Institutes
3.4.5: Academic Institutions
3.4.6: Others
4. MARKET TRENDS AND FORECAST ANALYSIS BY REGION FROM 2018 TO 2030
4.1: Global KRAS Inhibitors Market by Region
4.2: North American KRAS Inhibitors Market
4.2.2: North American KRAS Inhibitors Market by End Use: Clinic Laboratories, Cancer Diagnostic Centers, Hospitals, Cancer Research Institutes, Academic Institutions, and Others
4.3: European KRAS Inhibitors Market
4.3.1: European KRAS Inhibitors Market by Cancer Type: Lung Cancer, Pancreatic Cancer, Colorectal Cancer, and Others
4.3.2: European KRAS Inhibitors Market by End Use: Clinic Laboratories, Cancer Diagnostic Centers, Hospitals, Cancer Research Institutes, Academic Institutions, and Others
4.4: APAC KRAS Inhibitors Market
4.4.1: APAC KRAS Inhibitors Market by Cancer Type: Lung Cancer, Pancreatic Cancer, Colorectal Cancer, and Others
4.4.2: APAC KRAS Inhibitors Market by End Use: Clinic Laboratories, Cancer Diagnostic Centers, Hospitals, Cancer Research Institutes, Academic Institutions, and Others
4.5: ROW KRAS Inhibitors Market
4.5.1: ROW KRAS Inhibitors Market by Cancer Type: Lung Cancer, Pancreatic Cancer, Colorectal Cancer, and Others
4.5.2: ROW KRAS Inhibitors Market by End Use: Clinic Laboratories, Cancer Diagnostic Centers, Hospitals, Cancer Research Institutes, Academic Institutions, and Others
5. COMPETITOR ANALYSIS
5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter’s Five Forces Analysis
6. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS
6.1: Growth Opportunity Analysis
6.1.1: Growth Opportunities for the Global KRAS Inhibitors Market by Cancer Type
6.1.2: Growth Opportunities for the Global KRAS Inhibitors Market by End Use
6.1.3: Growth Opportunities for the Global KRAS Inhibitors Market by Region
6.2: Emerging Trends in the Global KRAS Inhibitors Market
6.3: Strategic Analysis
6.3.1: New Product Development
6.3.2: Capacity Expansion of the Global KRAS Inhibitors Market
6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global KRAS Inhibitors Market
6.3.4: Certification and Licensing
7. COMPANY PROFILES OF LEADING PLAYERS
7.1: Amgen
7.2: Boehringer Ingelheim
7.3: BridgeBio Pharma
7.4: Erasca
7.5: Innovent Biologics
7.6: Incyte
7.7: Mirati Therapeutics
7.8: Novartis
7.9: Jemincare
7.10: Cardiff Oncology
